• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    33 Stocks Moving In Friday's Mid-Day Session

    6/17/22 12:12:44 PM ET
    $ACOR
    $ADN
    $ADXN
    $AERC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Industrial Machinery/Components
    Miscellaneous
    Get the next $ACOR alert in real time by email

     

    Gainers

    • Revlon, Inc. (NYSE:REV) gained 81.5% to $3.54 following a report suggesting Reliance Industries is considering buying out the company, which recently filed for bankruptcy.
    • Mereo BioPharma Group plc (NASDAQ:MREO) surged 70% to $1.3580. AstraZeneca is rumored to be eyeing take over of Mereo BioPharma Group, according to a report in The Times.
    • Sesen Bio, Inc. (NASDAQ:SESN) gained 30% to $0.7700.
    • bluebird bio, Inc. (NASDAQ:BLUE) shares jumped 25.3% to $3.83. The FDA's Advisory Committee recently unanimously backed Bluebird bio’s gene therapy for a rare blood disorder.
    • Electric Last Mile Solutions, Inc. (NASDAQ:ELMS) jumped 44% to $0.4061 after jumping 100% on Thursday.
    • Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) gained 21.2% to $4.7250. Rhythm Pharmaceuticals entered into a Revenue Interest Financing Agreement with HealthCare Royalty Partners for a total investment of $100 million. The U.S. Food and Drug Administration (FDA) has approved Rhythm Pharmaceuticals’ supplemental New Drug Application (sNDA) for IMCIVREE® (setmelanotide), a melanocortin-4 receptor (MC4R) agonist, for patients with Bardet-Biedl syndrome (BBS).
    • PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) gained 21.2% to $0.6280.
    • Scholar Rock Holding Corporation (NASDAQ:SRRK) shares gained 20% to $5.83. Scholar Rock reported Phase 2 topaz trial extension data showing 'sizable and sustained motor function improvement at 24 months with apitegromab for non-ambulatory patients with types 2 and 3 spinal muscular atrophy.'
    • Seagen Inc. (NASDAQ:SGEN) shares rose 18.5% to $174.00. Merck is eyeing purchase of biotech Seagen, while other unnamed suitors are also eyeing Seagen, the Wall Street Journal said.
    • Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA) gained 16.5% to $4.0777. Comera was granted U.S. patent titled 'Excipient compounds for protein processing.'
    • SoundHound AI, Inc. (NASDAQ:SOUN) jumped 16.1% to $3.10.
    • Surrozen, Inc. (NASDAQ:SRZN) gained 15.5% to $2.5650. Surrozen recently initiated dosing in Phase 1 clinical trial of SZN-043 for severe alcoholic hepatitis.
    • Sapiens International Corporation N.V. (NASDAQ:SPNS) surged 15.1% to $24.09.
    • AeroClean Technologies, Inc. (NASDAQ:AERC) jumped 14.3% to $20.25.
    • Allakos Inc. (NASDAQ:ALLK) gained 14.2% to $2.9700.
    • Kinnate Biopharma Inc. (NASDAQ:KNTE) rose 14.1% to $9.39.
    • Sight Sciences, Inc. (NASDAQ:SGHT) jumped 12.9% to $8.46.
    • Calliditas Therapeutics AB (NASDAQ:CALT) rose 8.5% to $17.26.
    • Athersys, Inc. (NASDAQ:ATHX) rose 6.6% to $0.3411 after dropping more than 12% on Thursday.

     

     

    Losers

    • Renovare Environmental, Inc (NASDAQ:RENO) dipped 73.5% to $0.0450.
    • Addex Therapeutics Ltd (NASDAQ:ADXN) shares fell 55.3% to $1.61 after the company terminated its Phase 2b/3 study of Dipraglurant for dyskinesia associated with Parkinson's disease due to slow recruitment. The company suspended its guidance amid the termination.
    • ToughBuilt Industries, Inc. (NASDAQ:TBLT) fell 51.1% to $1.4899 after the company priced a $6 million offering.
    • Sidus Space, Inc. (NASDAQ:SIDU) fell 21.7% to $5.97.
    • Advent Technologies Holdings, Inc. (NASDAQ:ADN) dipped 20% to $3.1601. Advent Technologies recently announced it received notification of euro 782.1 million of funding from the Greek State for the IPCEI Green HiPo project.
    • Neptune Wellness Solutions Inc. (NASDAQ:NEPT) fell 19.5% to $2.19. Neptune Wellness appointed Raymond Silcock as Chief Financial Officer.
    • Acorda Therapeutics, Inc. (NASDAQ:ACOR) fell 19.1% to $0.5001. Acorda Therapeutics shares jumped around 55% on Thursday after the company announced Esteve Pharmaceuticals GmbH launched INBRIJA in Germany.
    • GlucoTrack, Inc. (NASDAQ:GCTK) declined 15.3% to $2.00.
    • Hillstream BioPharma, Inc. (NASDAQ:HILS) dropped 14.4% to $0.78.
    • Alvotech Ordinary Shares (NASDAQ:ALVO) fell 13.4% to $9.78.
    • Calumet Specialty Products Partners, L.P. (NASDAQ:CLMT) declined 12.2% to $10.13.
    • Heart Test Laboratories, Inc. (NASDAQ:HSCS) dropped 12% to $2.13. Heart Test Laboratories announced pricing of its IPO of 1.5 million units at a price of $4.25 per unit.
    • Dream Finders Homes, Inc. (NASDAQ:DFH) dipped 10.3% to $10.60. B of A Securities downgraded Dream Finders Homes from Neutral to Underperform and lowered the price target from $18 to $10.5.
    • Vivakor, Inc. (NASDAQ:VIVK) fell 8.8% to $2.27. Vivakor shares jumped 40% on Thursday after the company announced it signed a definitive agreement to acquire Silver Fuels Delhi and White Claw Colorado City.

     

    Get the next $ACOR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACOR
    $ADN
    $ADXN
    $AERC

    CompanyDatePrice TargetRatingAnalyst
    Scholar Rock Holding Corporation
    $SRRK
    1/9/2026$55.00Buy
    Citigroup
    Dream Finders Homes Inc.
    $DFH
    1/7/2026Mkt Perform
    Citizens JMP
    Sight Sciences Inc.
    $SGHT
    1/5/2026$9.00Neutral → Overweight
    Piper Sandler
    Mereo BioPharma Group plc
    $MREO
    12/30/2025$0.50Buy → Hold
    Jefferies
    Dream Finders Homes Inc.
    $DFH
    12/2/2025Neutral
    BTIG Research
    Rhythm Pharmaceuticals Inc.
    $RYTM
    11/25/2025$136.00Buy
    Citigroup
    Scholar Rock Holding Corporation
    $SRRK
    11/18/2025$42.00Outperform
    Wolfe Research
    Calumet Inc.
    $CLMT
    11/11/2025$15.00 → $18.00Hold
    TD Cowen
    More analyst ratings

    $ACOR
    $ADN
    $ADXN
    $AERC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on Scholar Rock with a new price target

    Citigroup initiated coverage of Scholar Rock with a rating of Buy and set a new price target of $55.00

    1/9/26 9:07:37 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Citizens JMP initiated coverage on Dream Finders Homes

    Citizens JMP initiated coverage of Dream Finders Homes with a rating of Mkt Perform

    1/7/26 9:09:56 AM ET
    $DFH
    Homebuilding
    Consumer Discretionary

    Sight Sciences upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Sight Sciences from Neutral to Overweight and set a new price target of $9.00

    1/5/26 8:36:47 AM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    $ACOR
    $ADN
    $ADXN
    $AERC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Tcg Crossover Gp Ii, Llc bought $202,534 worth of shares (9,357 units at $21.65) (SEC Form 4)

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    2/3/26 8:03:54 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Column Group Iii Gp, Lp bought $641,597 worth of shares (32,507 units at $19.74) (SEC Form 4)

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    1/20/26 7:35:33 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Kutzkey Tim bought $641,597 worth of shares (32,507 units at $19.74) (SEC Form 4)

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    1/20/26 7:31:54 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACOR
    $ADN
    $ADXN
    $AERC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Surrozen to Present at Upcoming Healthcare Investor Conference

    SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at an upcoming healthcare investor conference. Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 Presentation at 1:30 PM Eastern Time / 10:30 AM Pacific Time Interested parties may access the live audio webcast for the conference via the Investors section of the Surrozen website at https://investors.surr

    2/5/26 4:05:00 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit

    BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that Hunter C. Smith, Chief Financial Officer, will participate in a fireside chat at the upcoming Guggenheim Emerging Outlook: Biotech Summit 2026 conference on Wednesday, February 11 at 11:00 a.m. ET in New York. The fireside chat will be webcasted and available under "Events & Presentations" in the Investor Relations section of the Company's website at www.rhythmtx.com. A replay of the webcast will be available on the Rhythm website for 30 days fol

    2/5/26 8:00:00 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Addex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder Treatment

     Data published in Molecular Psychiatry Ad Hoc Announcement Pursuant to Art. 53 LR  Geneva, Switzerland, February 3, 2026 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today publication of data in Molecular Psychiatry1 demonstrating that targeting metabotropic glutamate receptor 7 (mGlu7) with negative allosteric modulators (NAM) could be transformative in the treatment of anxiety and fear-related disorders, such as post-traumatic stress disorder (PTSD). In the study, scientists from the Center for Psychiatric Neurosciences (CNP, CHUV/UNIL)

    2/3/26 1:00:00 AM ET
    $ADXN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $ADN
    $ADXN
    $AERC
    SEC Filings

    View All

    Vivakor Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Vivakor, Inc. (0001450704) (Filer)

    2/5/26 4:32:27 PM ET
    $VIVK
    Environmental Services
    Utilities

    SEC Form 144 filed by Rhythm Pharmaceuticals Inc.

    144 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)

    2/5/26 4:30:28 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Surrozen Inc.

    SCHEDULE 13G/A - Surrozen, Inc./DE (0001824893) (Subject)

    2/5/26 4:28:31 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACOR
    $ADN
    $ADXN
    $AERC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Smith Hunter C sold $702,744 worth of shares (6,628 units at $106.03), decreasing direct ownership by 5% to 125,537 units (SEC Form 4)

    4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)

    2/6/26 6:38:19 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Invus Global Management, Llc exercised 1,575,008 in-the-money shares at a strike of $7.35 (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    2/6/26 5:35:54 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Technology Officer Badawi David was granted 64,915 shares, increasing direct ownership by 3% to 1,977,188 units (SEC Form 4)

    4 - Sight Sciences, Inc. (0001531177) (Issuer)

    2/5/26 4:49:56 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    $ACOR
    $ADN
    $ADXN
    $AERC
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 8, 2023 - FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

    For Immediate Release: December 08, 2023 Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signali

    12/8/23 11:12:21 AM ET
    $BLUE
    $VRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    August 17, 2022 - FDA Approves First Cell-Based Gene Therapy to Treat Adult and Pediatric Patients with Beta-thalassemia Who Require Regular Blood Transfusions

    For Immediate Release: August 17, 2022 Today, the U.S. Food and Drug Administration approved Zynteglo (betibeglogene autotemcel), the first cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions.  “Today’s approval is an important advance in the treatment of beta-thalassemia, particularly in individuals who require ongoing

    8/17/22 2:12:27 PM ET
    $BLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for TARPEYO issued to CALLIDITAS THERAPEUTICS AB

    Submission status for CALLIDITAS THERAPEUTICS AB's drug TARPEYO (ORIG-1) with active ingredient BUDESONIDE has changed to 'Approval' on 12/15/2021. Application Category: NDA, Application Number: 215935, Application Classification: Type 5 - New Formulation or New Manufacturer

    12/20/21 3:40:41 PM ET
    $CALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $ADN
    $ADXN
    $AERC
    Leadership Updates

    Live Leadership Updates

    View All

    Sidus Space Appoints Aerospace Executive Kelle Wendling to Board of Directors

    Veteran Space and Defense Leader Brings Three Decades of Government Contracting, ISR, and Space Systems Expertise to Sidus Board CAPE CANAVERAL, Fla., Jan. 5, 2026 /PRNewswire/ -- Sidus Space, Inc. (NASDAQ:SIDU) ("Sidus" or the "Company"), an innovative space and defense technology company, today announced the appointment of accomplished aerospace and defense executive Kelle Wendling to its Board of Directors. Ms. Wendling brings more than three decades of executive leadership and government contracting experience across space systems, Intelligence, Surveillance and Reconnaissance (ISR), and Federal Aviation Administration (FAA) markets.

    1/5/26 8:30:00 AM ET
    $SIDU
    Telecommunications Equipment
    Telecommunications

    Sapiens Announces Leadership Appointments Following Closing of Acquisition by Advent

    Acquisition supports Sapiens' long-term growth, innovation and global expansionAfter twenty years leading Sapiens, Roni Al-Dor has decided to step down as CEO and PresidentNew leadership appointments to support the next phase of transformationLONDON, Dec. 17, 2025 /PRNewswire/ -- Sapiens International Corporation N.V. ("Sapiens") today announces a series of senior leadership appointments that will support the company's next phase of transformation and global growth. These appointments follow the successful closing of Sapiens' acquisition by Advent, a leading global private equity investor. The transaction was first announced on August 13, 2025, was approved by Sapiens shareholders at the Ext

    12/17/25 12:34:00 PM ET
    $SPNS
    Computer Software: Prepackaged Software
    Technology

    Glucotrack Reports Third Quarter 2025 Financial Results and Provides Update on Recent Corporate Highlights

    Company to submit Investigational Device Exemption (IDE) to FDA for novel CBGM technology in Spring 2026 Expanded clinical advisory team with appointment of pain management and medical technology expert, Usman Latif, MD, MBA Strengthened balance sheet, cash and cash equivalents expected to fund operations through March 2026, including long-term feasibility clinical trials and achievement of related milestones Rutherford, NJ, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today reported financial results

    11/13/25 4:05:00 PM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    $ACOR
    $ADN
    $ADXN
    $AERC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Rhythm Pharmaceuticals Inc.

    SC 13G - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)

    11/14/24 9:50:26 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Scholar Rock Holding Corporation

    SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)

    11/14/24 9:00:58 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sidus Space Inc.

    SC 13G/A - Sidus Space Inc. (0001879726) (Subject)

    11/14/24 7:31:47 PM ET
    $SIDU
    Telecommunications Equipment
    Telecommunications

    $ACOR
    $ADN
    $ADXN
    $AERC
    Financials

    Live finance-specific insights

    View All

    Vivakor Signs Letter of Intent to Sell its Midstream Business in Oklahoma STACK Play for $36 Million to Olenox Industries

    Dallas, TX, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Vivakor, Inc. (OTC:VIVK) ("Vivakor" or the "Company"), an integrated provider of energy transportation, storage, reuse, and remediation service, today announced that it has executed a non-binding Letter of Intent to sell its midstream business and transportation assets of CPE Gathering MidCon, LLC ("CPE Gathering") to Olenox Industries, Inc. (NASDAQ:OLOX) for approximately $36 million. Vivakor is the owner and operator of the Omega pipeline system, an integrated crude-oil gathering, transportation, terminaling and pipeline connection platform serving the Oklahoma STACK play. The transaction, valued at approximately $36 million, will be paid i

    2/2/26 8:30:00 AM ET
    $OLOX
    $VIVK
    RETAIL: Building Materials
    Consumer Discretionary
    Environmental Services
    Utilities

    Olenox Industries Signs Letter of Intent to Acquire Vivakor's Midstream Business in Oklahoma STACK Play

    CONROE, Texas, Jan. 29, 2026 (GLOBE NEWSWIRE) -- via IBN -- Olenox Industries Inc. (NASDAQ:OLOX) ("Olenox Industries" or the "Company"), today announced that it has executed a non-binding Letter of Intent to acquire the midstream business and transportation assets of CPE Gathering MidCon, LLC ("CPE Gathering") from Vivakor, Inc. (OTC:VIVK), owner and operator of the Omega pipeline system, an integrated crude-oil gathering, transportation, terminaling and pipeline connection platform serving the Oklahoma STACK play.   The transaction, valued at approximately $36 million, will be paid in a combination of cash, promissory note, common and preferred stock, and is based on $4.56 million in ann

    1/29/26 8:30:00 AM ET
    $OLOX
    $VIVK
    RETAIL: Building Materials
    Consumer Discretionary
    Environmental Services
    Utilities

    Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Scholar Rock (NASDAQ:SRRK, the "Company")) today announced that the company granted inducement equity awards covering an aggregate of 35,200 shares of its common stock to two newly hired employees, consisting of inducement stock options to purchase an aggregate of 20,400 shares of common stock and inducement restricted stock units, covering an aggregate of 14,800 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth in the Company's 2022 Inducement Equity Plan (the "Plan") and the award agreements thereunder. The Plan, initially adopted by the Company's board of directors on June 16, 2022, and as amended from time to time, is used

    1/16/26 4:15:00 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care